VRCA insider transaction filings
Verrica Pharmaceuticals Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen VRCA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 4 filings by 4 insiders — 42,230 shares, $210,890 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 20,000 shares @ $5.06 ($101,200) by Rieger Jayson, filed 2026-08-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Rieger Jayson — CEO and President, Director | 1 | 2 legs · 25,000 sh · $125,750 | — | — |
| Rosenberg Noah L. — CMO | 1 | 2 legs · 6,230 sh · $30,610 | — | — |
| Zawitz David — Chief Operating Officer | 1 | 1 leg · 6,000 sh · $29,880 | — | — |
| Kirby John J. — Interim CFO | 1 | 1 leg · 5,000 sh · $24,650 | — | — |
Recent Form 4 filings — Verrica Pharmaceuticals Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Kirby John J. — Interim CFO | Purchase (P): 5,000 @ $4.93 | EDGAR |
| 2026-08-18 | 4 | Rosenberg Noah L. — CMO | Purchase (P): 4,200 @ $4.91 · Purchase (P): 2,030 @ $4.92 | EDGAR |
| 2026-08-18 | 4 | Rieger Jayson — CEO and President, Director | Purchase (P): 20,000 @ $5.06 · Purchase (P): 5,000 @ $4.91 | EDGAR |
| 2026-08-18 | 4 | Zawitz David — Chief Operating Officer | Purchase (P): 6,000 @ $4.98 | EDGAR |
| 2026-06-09 | 4 | Zawitz David — Chief Operating Officer | Grant/award (A): 171,340 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rieger Jayson — CEO and President, Director | Grant/award (A): 512,269 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Eichenfield Lawrence — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Nguyen Diem — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Corcoran Gavin — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rosenberg Noah L. — CMO | Grant/award (A): 233,840 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | PRYGOCKI MARK A SR — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-12-30 | 4 | Kirby John J. — Interim CFO | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-11-25 | 4 | Zawitz David — Chief Operating Officer | Purchase (P): 10,000 @ $4.24 · Purchase (P): 2,500 (derivative) | EDGAR |
| 2025-11-25 | 4 | Rieger Jayson — CEO and President, Director | Purchase (P): 94,311 @ $4.24 · Purchase (P): 23,577 (derivative) | EDGAR |
| 2025-11-25 | 4 | Rosenberg Noah L. — CMO | Purchase (P): 2,357 @ $4.24 · Purchase (P): 589 (derivative) | EDGAR |
| 2025-11-25 | 4 | Kirby John J. — Interim CFO | Purchase (P): 3,536 @ $4.24 · Purchase (P): 884 (derivative) | EDGAR |
| 2025-11-25 | 4 | Manning Paul B — Director, 10% owner | Purchase (P): 1,375,380 @ $4.24 · Purchase (P): 2,750,762 @ $4.24 · Purchase (P): 343,845 (derivative) · Purchase (P): 687,690 (derivative) | EDGAR |
| 2025-06-09 | 4 | Corcoran Gavin — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nguyen Diem — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Eichenfield Lawrence — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PRYGOCKI MARK A SR — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Corcoran Gavin — Director | Grant/award (A): 17,502 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | Rosenberg Noah L. — CMO | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Rieger Jayson — CEO and President, Director | Grant/award (A): 850,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Hayes Christopher G. — CHIEF LEGAL OFFICER | Sale (S): 4,315 @ $0.65 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4/A | Goldenberg Gary — Chief Medical Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Kohler Terry — CHIEF FINANCIAL OFFICER | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Hayes Christopher G. — CHIEF LEGAL OFFICER | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | White Ted — PRESIDENT AND CEO, Director | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2025-02-06 | 4/A | Bonaccorso Joe — CHIEF COMMERCIAL OFFICER | Grant/award (A): 125,000 @ $0 | EDGAR |
| 2024-12-09 | 4 | Zawitz David — Chief Operating Officer | Grant/award (A): 950,000 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Rieger Jayson — CEO and President, Director | Purchase (P): 280,898 · Gift (G): 50,000 @ $0 · Purchase (P): 140,449 (derivative) · Purchase (P): 140,449 (derivative) | EDGAR |
| 2024-11-26 | 4 | Stalfort John A III — Director | Purchase (P): 1,123,595 · Gift (G): 50,000 @ $0 · Purchase (P): 561,797 (derivative) · Purchase (P): 561,797 (derivative) | EDGAR |
| 2024-11-26 | 4 | Manning Paul B — Director, 10% owner | Purchase (P): 18,426,966 · Purchase (P): 4,494,382 · Gift (G): 450,000 @ $0 · Purchase (P): 9,213,483 (derivative) · Purchase (P): 9,213,483 (derivative) · Purchase (P): 2,247,191 (derivative) · +1 more | EDGAR |
| 2024-11-06 | 4 | Rieger Jayson — CEO and President, Director | Grant/award (A): 2,000,000 (derivative) @ $0 | EDGAR |
| 2024-11-06 | 4 | Kirby John J. — Interim CFO | Grant/award (A): 54,267 @ $0 | EDGAR |
| 2024-10-11 | 4 | Hayes Christopher G. — CHIEF LEGAL OFFICER | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-09-23 | 4 | Manning Paul B — Director, 10% owner | Gift (G): 2,675,611.25 @ $0 · Gift (G): 891,870.41 @ $0 · Gift (G): 891,870.42 @ $0 · Gift (G): 891,870.42 @ $0 | EDGAR |
| 2024-08-28 | 4 | Hayes Christopher G. — CHIEF LEGAL OFFICER | Sale (S): 26,183 @ $2.66 · Sale (S): 9,530 @ $2.46 | EDGAR |
| 2024-08-28 | 4 | Goldenberg Gary — Chief Medical Officer | Sale (S): 9,888 @ $2.66 · Sale (S): 3,601 @ $2.46 | EDGAR |
| 2024-08-28 | 4 | Bonaccorso Joe — CHIEF COMMERCIAL OFFICER | Sale (S): 24,709 @ $2.66 · Sale (S): 8,993 @ $2.46 | EDGAR |
| 2024-08-28 | 4 | Kohler Terry — CHIEF FINANCIAL OFFICER | Sale (S): 21,820 @ $2.66 · Sale (S): 7,899 @ $2.46 | EDGAR |
| 2024-08-28 | 4 | White Ted — PRESIDENT AND CEO, Director | Sale (S): 24,979 @ $2.66 · Sale (S): 9,021 @ $2.46 | EDGAR |
| 2024-07-23 | 4 | Bonaccorso Joe — CHIEF COMMERCIAL OFFICER | Sale (S): 25,461 @ $7.06 · Sale (S): 115 @ $6.98 | EDGAR |
| 2024-07-23 | 4 | White Ted — PRESIDENT AND CEO, Director | Sale (S): 32,469 @ $7.06 · Sale (S): 154 @ $6.98 | EDGAR |
| 2024-07-23 | 4 | Goldenberg Gary — Chief Medical Officer | Sale (S): 18,421 @ $7.06 · Sale (S): 86 @ $6.98 | EDGAR |
| 2024-07-23 | 4 | Hayes Christopher G. — CHIEF LEGAL OFFICER | Sale (S): 21,649 @ $7.06 · Sale (S): 91 @ $6.98 | EDGAR |
| 2024-06-07 | 4 | Eichenfield Lawrence — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Ballaron Craig — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | PRYGOCKI MARK A SR — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Verrica Pharmaceuticals Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-07-23 | 8-K | 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VRCA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →